| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Creatinine-D3 does not exert a pharmacological action; rather, it is used as an analytical standard. Its role is to serve as an internal standard for the quantification of endogenous creatinine in biological samples such as serum, plasma, and urine. Creatinine itself is synthesized in the kidney, liver, and pancreas and is transported in the blood to muscle and brain, where it is phosphorylated to phosphocreatine. By using Creatinine-D3 as an internal standard, researchers can accurately measure creatinine levels, which are important biomarkers for renal function assessment and muscle mass measurement.
|
|---|---|
| ln Vitro |
In vitro, Creatinine-D3 is used as an internal standard in the development and validation of LC-MS and GC-MS methods for creatinine quantification. It is spiked into biological samples at a known concentration prior to sample preparation. The ratio of the peak area of endogenous creatinine to that of Creatinine-D3 is used to calculate the concentration of creatinine in the sample. This approach corrects for variability in the analytical process, including ion suppression, matrix effects, and extraction efficiency. Creatinine-D3 is also used in method validation studies to assess accuracy, precision, and linearity.
|
| ln Vivo |
In vivo, Creatinine-D3 is not administered as a therapeutic agent; it is used exclusively as an analytical standard. However, its use in quantifying creatinine levels in clinical samples has important implications for patient care. Accurate measurement of creatinine is essential for estimating glomerular filtration rate (eGFR), which is used to diagnose and monitor kidney disease. Creatinine-D3 is also used in urine drug testing and forensic analysis to correct for sample dilution and ensure accurate results. Its application in these settings helps to improve the reliability of clinical diagnoses and forensic determinations.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Creatinine-D3, as it is an analytical standard rather than a pharmacologically active compound. However, its use in analytical chemistry involves validation of the mass spectrometric method. The assay typically involves preparing a series of calibration standards containing known concentrations of creatinine and a fixed concentration of Creatinine-D3. These standards are analyzed by LC-MS or GC-MS, and the peak area ratios are plotted against the concentrations to generate a calibration curve. The method is then validated for accuracy, precision, and linearity according to regulatory guidelines.
|
| Cell Assay |
In vitro cellular experiments are not applicable to Creatinine-D3, as it is an analytical standard used in mass spectrometry. The compound is not used to treat cells or study biological pathways. Instead, it is added to biological samples such as cell culture media or lysates to serve as an internal standard for the quantification of creatinine. The samples are then processed and analyzed by LC-MS or GC-MS. The use of Creatinine-D3 in this context ensures that the quantification of creatinine is accurate and reproducible, even in complex biological matrices.
|
| Animal Protocol |
In vivo animal studies are not applicable to Creatinine-D3, as it is not a therapeutic agent. However, the compound is used in the analysis of samples from animal studies. For example, in pharmacokinetic or toxicology studies, Creatinine-D3 is used as an internal standard to measure creatinine levels in plasma or urine samples from treated animals. This helps to monitor renal function and detect any drug-induced nephrotoxicity. The accurate quantification of creatinine is essential for interpreting the results of these studies and assessing the safety of test compounds.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Creatinine-D3, as it is used as an analytical standard rather than a therapeutic agent. The compound is not designed to exert a pharmacological effect, and its distribution, metabolism, and excretion are not studied in the context of drug development. Instead, Creatinine-D3 is used to quantify endogenous creatinine, which is a biomarker of renal function. The half-life of endogenous creatinine in the body is approximately 3-4 hours, and it is cleared primarily by glomerular filtration.
|
| Toxicity/Toxicokinetics |
Toxicology is not applicable to Creatinine-D3, as it is used as an analytical standard rather than a therapeutic agent. The compound is not intended for human or animal administration, and its toxicity profile has not been characterized. However, as a stable isotope-labeled compound, Creatinine-D3 is considered safe for handling in the laboratory under standard safety precautions. It is not known to be toxic, mutagenic, or carcinogenic. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
Creatinine-D3 is a critical tool in clinical chemistry and bioanalytical research, serving as the gold standard internal standard for the quantification of creatinine by mass spectrometry. Its use corrects for matrix effects and ion suppression, ensuring accurate and reliable results. Creatinine is an important biomarker for renal function, and its accurate measurement is essential for diagnosing and monitoring kidney disease. Creatinine-D3 is also used in urine drug testing, forensic analysis, and clinical diagnostics. Its stable isotope labeling ensures that it behaves identically to endogenous creatinine during sample preparation and analysis, making it an indispensable tool in analytical chemistry.
|
| Molecular Formula |
C?H?D?N?O
|
|---|---|
| Molecular Weight |
113.11788
|
| Exact Mass |
116.077
|
| CAS # |
143827-20-7
|
| PubChem CID |
136212971
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
255ºC (dec.)(lit.)
|
| Index of Refraction |
1.651
|
| LogP |
-1.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
142
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N1CC(=O)NC1=N
|
| InChi Key |
DDRJAANPRJIHGJ-FIBGUPNXSA-N
|
| InChi Code |
InChI=1S/C4H7N3O/c1-7-2-3(8)6-4(7)5/h2H2,1H3,(H2,5,6,8)/i1D3
|
| Chemical Name |
2-imino-1-(trideuteriomethyl)imidazolidin-4-one
|
| Synonyms |
CreatinineD3; Creatinine D3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~83.33 mg/mL (~717.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.8402 mL | 44.2008 mL | 88.4017 mL | |
| 5 mM | 1.7680 mL | 8.8402 mL | 17.6803 mL | |
| 10 mM | 0.8840 mL | 4.4201 mL | 8.8402 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
